CA2716755A1 - Protein kinase modulators - Google Patents

Protein kinase modulators Download PDF

Info

Publication number
CA2716755A1
CA2716755A1 CA2716755A CA2716755A CA2716755A1 CA 2716755 A1 CA2716755 A1 CA 2716755A1 CA 2716755 A CA2716755 A CA 2716755A CA 2716755 A CA2716755 A CA 2716755A CA 2716755 A1 CA2716755 A1 CA 2716755A1
Authority
CA
Canada
Prior art keywords
optionally substituted
compound
alkyl
ring
lcms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2716755A
Other languages
English (en)
French (fr)
Inventor
Peter C. Chua
Mustapha Haddach
Johnny Yasuo Nagasawa
Fabrice Pierre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cylene Pharmaceuticals Inc
Original Assignee
Cylene Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cylene Pharmaceuticals Inc filed Critical Cylene Pharmaceuticals Inc
Publication of CA2716755A1 publication Critical patent/CA2716755A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2716755A 2008-02-29 2009-02-28 Protein kinase modulators Abandoned CA2716755A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6784508P 2008-02-29 2008-02-29
US61/067,845 2008-02-29
US10390808P 2008-10-08 2008-10-08
US61/103,908 2008-10-08
PCT/US2009/035609 WO2009108912A1 (en) 2008-02-29 2009-02-28 Protein kinase modulators

Publications (1)

Publication Number Publication Date
CA2716755A1 true CA2716755A1 (en) 2009-09-03

Family

ID=41016490

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2716755A Abandoned CA2716755A1 (en) 2008-02-29 2009-02-28 Protein kinase modulators

Country Status (8)

Country Link
US (2) US8168651B2 (enExample)
EP (1) EP2259678A4 (enExample)
JP (1) JP2011515337A (enExample)
CN (1) CN102036561A (enExample)
AU (1) AU2009219154A1 (enExample)
CA (1) CA2716755A1 (enExample)
MX (1) MX2010009445A (enExample)
WO (1) WO2009108912A1 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2061765T3 (en) 2006-09-01 2015-01-26 Senhwa Biosciences Inc Serine-threonine protein kinase AND PARP-MODULATOR
SI2268618T1 (sl) 2008-03-03 2015-09-30 Novartis Ag Spojine in sestavki kot modulatorji aktivnosti TLR
US20100173013A1 (en) * 2009-01-08 2010-07-08 Denis Drygin Treatment of neoplastic disorders using combination therapies
SG175210A1 (en) * 2009-04-17 2011-11-28 Cylene Pharmaceuticals Inc Method of treating disorders associated with protein kinase ck2 activity
US9968574B2 (en) * 2009-05-15 2018-05-15 The University Of Kentucky Research Foundation Treatment of MCI and Alzheimer's disease
WO2011025859A1 (en) * 2009-08-26 2011-03-03 Cylene Pharmaceuticals, Inc. Condensed quinolines as protein kinase modulators
SI2473510T1 (sl) * 2009-09-03 2014-10-30 Bristol-Myers Squibb Company Jak2 inhibitorji in njihova uporaba za zdravljenje mieloproliferativnih bolezni in raka
AU2010295622A1 (en) * 2009-09-16 2012-05-10 Cylene Pharmaceuticals, Inc. Tricyclic compounds and pharmaceutical uses thereof
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
LT2496567T (lt) 2009-11-05 2017-11-27 Rhizen Pharmaceuticals S.A. Nauji benzopirano kinazės moduliatoriai
US8853235B2 (en) * 2009-11-23 2014-10-07 Senhwa Biosciences, Inc. Polymorphs and salts of a kinase inhibitor
US10106798B2 (en) 2010-01-05 2018-10-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) FLT3 receptor antagonists for the treatment or the prevention of pain disorders
US9109227B2 (en) 2010-01-05 2015-08-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) FLT3 receptor antagonists for the treatment or the prevention of pain disorders
TWI503323B (zh) * 2010-03-29 2015-10-11 Oncotherapy Science Inc 三環化合物以及含此化合物之ｐｂｋ抑制劑
PT2705029T (pt) 2011-05-04 2019-02-01 Rhizen Pharmaceuticals S A Novos compostos como moduladores de proteína quinases
CN102731431A (zh) * 2012-06-20 2012-10-17 盛世泰科生物医药技术(苏州)有限公司 一种5-溴噻唑-4-甲酸的制备方法
PT2870157T (pt) 2012-07-04 2017-11-27 Rhizen Pharmaceuticals S A Inibidores seletivos de delta pi3k
EP2943485B1 (en) 2013-01-14 2017-09-20 Incyte Holdings Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
TWI662030B (zh) 2013-01-15 2019-06-11 英塞特控股公司 適用作ｐｉｍ激酶抑制劑之噻唑甲醯胺及吡啶甲醯胺化合物
AU2014293013A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
US9556197B2 (en) 2013-08-23 2017-01-31 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
CN108341774B (zh) * 2017-01-25 2022-07-19 首药控股(北京)股份有限公司 取代的喹啉酮类抑制剂
WO2019090205A1 (en) 2017-11-06 2019-05-09 Snap Bio, Inc. Pim kinase inhibitor compositions, methods, and uses thereof
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
CN111936484A (zh) 2017-12-22 2020-11-13 拉文纳制药公司 作为磷脂酰肌醇磷酸激酶抑制剂的色烯并吡啶衍生物
US11071727B2 (en) 2018-01-26 2021-07-27 Northwestern University Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors
US11332476B2 (en) * 2018-04-03 2022-05-17 3Sm Biotron Inc. Fms-like tyrosine kinase inhibitors
SG11202104371XA (en) * 2018-11-15 2021-05-28 Nippon Shinyaku Co Ltd 1,3,4-oxadiazolone compound and pharmaceutical
CN109369526A (zh) * 2018-12-19 2019-02-22 桂林理工大学 一种两面针碱衍生物的合成方法及其抗肿瘤应用
GB201902759D0 (en) 2019-02-28 2019-04-17 Benevolentai Bio Ltd Compositions and uses thereof
TW202112784A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之𠳭唏并嘧啶衍生物
CN111320605A (zh) * 2020-03-09 2020-06-23 吉林工程技术师范学院 一种银催化的含氟菲啶衍生物的制备方法
CN113444084A (zh) * 2020-03-26 2021-09-28 东南大学 一类抗肿瘤化合物及其制备与用途
CN113444085B (zh) * 2020-03-26 2022-04-08 东南大学 一种具有克服顺铂耐药的抗肿瘤化合物及其制备与应用
JP2023520882A (ja) * 2020-03-30 2023-05-22 センホア・バイオサイエンシーズ・インコーポレイテッド 肝臓指向性のウイルス感染症、特にｂ型肝炎およびｄ型肝炎を処置するための抗ウイルス化合物および方法
EP3967307A1 (en) 2020-09-15 2022-03-16 Instytut Hematologii I Transfuzologii Use of pim kinase inhibitors to augment the efficacy of anti-cd20 antibody-based therapies in hematologic malignancies and non-malignant conditions
AU2021360636A1 (en) * 2020-10-16 2023-06-15 Shanghai De Novo Pharmatech Co., Ltd. Triheterocyclic derivative, and pharmaceutical composition and application thereof
GB202102895D0 (en) 2021-03-01 2021-04-14 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
WO2023126951A1 (en) * 2022-01-03 2023-07-06 Yeda Research And Development Co. Ltd. Inhibitors of autophagy-related protein-protein interactions
WO2023225586A2 (en) * 2022-05-19 2023-11-23 4M Therapeutics Inc. Novel azaphenantrhene derivatives as inhibitors of glycogen synthase kinase 3 for therapeutic use
CN120641422A (zh) * 2023-02-03 2025-09-12 米拉蒂治疗公司 取代的三环化合物
US11987581B1 (en) 2023-12-19 2024-05-21 King Faisal University Imidazo[1,2-c]pyrido[3,4-e]pyrimidine-2-carboxylic acids as CK2 inhibitors
US12024518B1 (en) 2023-12-20 2024-07-02 King Faisal University Pyrazolo[4,3-C][1,6]naphthyridines as CK2 inhibitors
US12012414B1 (en) 2024-01-04 2024-06-18 King Faisal University Imidazo[1,5-a]pyrido[4,3-e]pyrimidines as CK2 inhibitors
US11964974B1 (en) 2024-01-08 2024-04-23 King Faisal University Imidazo[1,2-c]pyrido[3,4-e]pyrimidine-3-carboxylic acids as CK2 inhibitors
US11981676B1 (en) 2024-01-16 2024-05-14 King Faisal University Pyrazolo[4,3-c][2,6]naphthyridines as CK2 inhibitors
US12187726B1 (en) 2024-02-06 2025-01-07 King Faisal University Imidazo[1,5-a]pyrido[4,3-e]pyrazines as CK2 inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991064A (en) * 1975-01-17 1976-11-09 Warner-Lambert Company Benzonaphthyridines
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
MY148521A (en) * 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
WO2007007152A2 (en) 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat metastatic cancers and chloroma
MX2008002165A (es) * 2005-08-16 2008-04-29 Irm Llc Compuestos y composiciones como inhibidores de la proteina cinasa.
BRPI0619785A2 (pt) * 2005-12-13 2011-10-18 Wyeth Corp composto, composição e método para o tratamento de um transtorno proliferativo e método de prepraração
DK2061765T3 (en) * 2006-09-01 2015-01-26 Senhwa Biosciences Inc Serine-threonine protein kinase AND PARP-MODULATOR
CA2663856A1 (en) 2006-09-28 2008-04-10 Exelixis, Inc. Jak-2 modulators and methods of use
WO2008109613A1 (en) * 2007-03-05 2008-09-12 Wyeth Benzo[c][2,7]naphthyridine derivatives, and their use as kinase inhibitors

Also Published As

Publication number Publication date
CN102036561A (zh) 2011-04-27
JP2011515337A (ja) 2011-05-19
EP2259678A1 (en) 2010-12-15
EP2259678A4 (en) 2011-07-27
MX2010009445A (es) 2011-05-25
WO2009108912A1 (en) 2009-09-03
US8168651B2 (en) 2012-05-01
US20120208792A1 (en) 2012-08-16
AU2009219154A1 (en) 2009-09-03
US20090239859A1 (en) 2009-09-24

Similar Documents

Publication Publication Date Title
US8168651B2 (en) Protein kinase modulators
US12384782B2 (en) Inhibitors of kinase networks and uses thereof
CN102316733B (zh) 杂环化合物和使用方法
US8716297B2 (en) Chemical entities to be used for Wee1 inhibition for the treatment of cancer
US8354422B2 (en) Pyrimidine inhibitors of kinase activity
US8536180B2 (en) Pyrimidine inhibitors of kinase activity
ES2477221T3 (es) Compuestos que contienen nitrógeno y sus composiciones farmacéuticas para el tratamiento de la fibrilaci�n auricular
US8486933B2 (en) Pyrimidine inhibitors of kinase activity
CA2827648A1 (en) Tricyclic inhibitors of kinases
CA2864142A1 (en) Pyridopyrimidinone inhibitors of kinases
CA2661842A1 (en) Tricyclic heteroaryl compounds and their use as serine-threonine protein kinases and parp modulators
US20130102590A1 (en) Pyridopyrimidinone inhibitors of kinases
AU2014244263A1 (en) CDK9 kinase inhibitors

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20140228